-

INVESTOR ALERT: Kirby McInerney LLP Continues Investigation of Shareholder Claims on Behalf of CareDx, Inc. (CDNA) Investors

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against CareDx, Inc. (“CareDx” or the “Company”) (NASDAQ: CDNA). The investigation concerns whether CareDx has violated the federal securities laws and/or engaged in other unlawful business practices.

On January 25, 2021, the Company sold 1,923,077 shares of its common stock through an underwritten public offering at a public offering price of $91.00 per share.

On October 28, 2021, after the market closed, CareDx released Q3 2021 financial results in which the Company disclosed that the U.S. Department of Justice (“DOJ”) had recently served a civil investigatory demand requesting documents in connection with a False Claims Act investigation. The DOJ is investigating business practices related to CareDx’s kidney testing and phlebotomy services. The Company also disclosed that it received a subpoena from the U.S. Securities and Exchange Commission (“SEC”) for similar issues as well as certain accounting and public reporting practices, and the Company received an information request from an unnamed state agency. On this news, the Company’s share price declined by $19.34 per share, or approximately 27.5%, from $70.34 per share to close at $51.00 per share on October 29, 2021.

If you purchased or otherwise acquired CareDx securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney LLP at 212-371-6600, by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website: http://www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-371-6600
https://www.kmllp.com
investigations@kmllp.com

Kirby McInerney LLP

NASDAQ:CDNA

Release Versions
$Cashtags

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-371-6600
https://www.kmllp.com
investigations@kmllp.com

More News From Kirby McInerney LLP

Securities Class Action Filed Against Compass, Inc. On Behalf of Former Anywhere Real Estate Inc. Investors – Contact Kirby McInerney LLP If You Acquired COMP Shares in Exchange for Your HOUS Securities 

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of former Anywhere Real Estate Inc. (“Anywhere”) (formerly trading as NYSE: HOUS) investors who acquired Compass, Inc. (“Compass” or the “Company”) (NYSE: COMP) common stock in direct exchange for Anywhere securities pursuant to the S-4 registration statement, 424B3 prospectus, and related oral communications (collectively, with materials incorporated therein, the “Regist...

Securities Class Action Filed Against Duolingo, Inc. – DUOL Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Duolingo, Inc. (“Duolingo” or the “Company”) (NASDAQ: DUOL) securities between May 2, 2025 and February 26, 2026, inclusive (“the Class Period”). If you suffered a loss on your Duolingo investments, you have until December 7, 2026 to request lead plaintiff appointment.[CONTACT THE FIRM IF YOU SUFFERED A LOSS]Investors are encouraged to fill out t...

Kirby McInerney LLP Alerts Investors Who Acquired Beta Bionics, Inc. BBNX Securities Between July 30, 2025 and February 24, 2026 of Pending Lawsuit

NEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP reminds Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) investors of the November 3, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Investors are encouraged to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost.[CONTACT THE...
Back to Newsroom